Commentary
Alectinib for the management of ALK-positive non-small cell lung cancer brain metastases
Abstract
Anaplastic lymphoma kinase (ALK) rearrangements were first identified as an oncogenic driver in non-small cell lung cancers (NSCLC) in 2007, specifically the gene re-arrangement between ALK and echinoderm microtubule-associated protein like 4 (EML4) (1).
